IDEXX Laboratories, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes diagnostic products, equipment, and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. The company offers an extensive portfolio of in-clinic analyzers including the Catalyst One Chemistry Analyzer, ProCyte Dx Hematology Analyzer, SediVue Dx Urine Sediment Analyzer, and SNAP point-of-care tests; reference laboratory services for advanced diagnostics; veterinary software solutions such as IDEXX Neo and Cornerstone practice management software, VetLab Station laboratory information management system, and client communication tools; diagnostic imaging systems like ImageVue DR50 and EliteVision; and specialized tests for ruminants (e.g., BVDV, IBR/BHV-1, Johne's Disease), poultry (e.g., IBV, IBD), swine (e.g., PRRS, PEDV), equine health (e.g., EHV-1/4 RealPCR, EPM tests), and water quality microbiological detection serving over 2.5 billion people. IDEXX also provides OPTI Medical Systems for human point-of-care and laboratory diagnostics. Founded in 1983 and headquartered in Westbrook, Maine, the company operates in over 175 countries through its three main segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD), with additional EMEA headquarters in Hoofddorp, Netherlands, and approximately 10,000 employees worldwide. Recent developments include the strong adoption of the inVue Dx Cellular Analyzer with over 2,400 units installed in Q2 2025, surpassing expectations and prompting a full-year installation forecast increase to 5,500 units; the June 2025 launch of the Catalyst Cortisol Test, the third Catalyst platform expansion that year, enhancing point-of-care diagnostics for endocrine disorders like Addison's and Cushing's disease in dogs; the North American rollout of IDEXX Cancer Dx; upward revisions to 2025 revenue guidance to $4.27 billion-$4.30 billion and EPS to $12.81-$13.01 amid 11% Q2 revenue growth and 13% Q3 growth driven by recurring CAG diagnostics; and sustained R&D investment at about 5.75% of revenue to support platform expansions, AI-driven solutions, molecular tests, international commercial footprint growth in three countries by 2026, and software enhancements.
ALC vs. IDXX: Which Stock Is the Better Value Option?
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock?
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 96/100
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Idexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound?
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
The Biology Came First.
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
IDEXX Laboratories Inc (IDXX) Shares Fall 5.0% -- What GF Score of 99 Tells Investors
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up
Idexx (IDXX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates